264 related articles for article (PubMed ID: 2249319)
1. [Pulmonary changes in progressive systemic sclerosis].
Yao WZ
Zhonghua Jie He He Hu Xi Za Zhi; 1990 Jun; 13(3):157-9, 191. PubMed ID: 2249319
[TBL] [Abstract][Full Text] [Related]
2. Lung involvement in systemic sclerosis.
Silver RM; Miller KS
Rheum Dis Clin North Am; 1990 Feb; 16(1):199-216. PubMed ID: 2406808
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary functions in children with progressive systemic sclerosis.
Garty BZ; Athreya BH; Wilmott R; Scarpa N; Doughty R; Douglas SD
Pediatrics; 1991 Dec; 88(6):1161-7. PubMed ID: 1956732
[TBL] [Abstract][Full Text] [Related]
4. [The correlations of respiratory function tests, chest roentgenographic manifestations and respiratory symptoms in the patients with systemic sclerosis, using a scoring-method for symptoms].
Kikuchi K; Igarashi A; Ishibashi Y; Inokuma S; Takehara K
Nihon Hifuka Gakkai Zasshi; 1990 May; 100(6):695-700. PubMed ID: 2214236
[TBL] [Abstract][Full Text] [Related]
5. Static lung mechanics in patients of progressive systemic sclerosis without obvious pulmonary involvement.
Gupta D; Aggarwal AN; Sud A; Jindal SK
Indian J Chest Dis Allied Sci; 2001; 43(2):97-101. PubMed ID: 11529415
[TBL] [Abstract][Full Text] [Related]
6. [Pulmonary involvement in sclerodermia].
Paone G; Di Michele L; Mattia P; Tonnarini R; Lucifora V; Fiorucci F
Minerva Med; 1994 Jun; 85(6):293-300. PubMed ID: 8084431
[TBL] [Abstract][Full Text] [Related]
7. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
[TBL] [Abstract][Full Text] [Related]
8. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis.
Jacobsen S; Ullman S; Shen GQ; Wiik A; Halberg P
J Rheumatol; 2001 Nov; 28(11):2454-9. PubMed ID: 11708418
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive diagnostic and functional evaluation of cardiac and pulmonary involvement in systemic sclerosis.
Sergiacomi G; De Nardo D; Capria A; Manenti G; Fabiano S; Borzi M; De Sanctis G; Konda D; Sperandio M; Schillaci O; Masala S; Simonetti G; Fontana L
In Vivo; 2004; 18(2):229-35. PubMed ID: 15113051
[TBL] [Abstract][Full Text] [Related]
10. Role of inflammation in the lung disease of systemic sclerosis: comparison with idiopathic pulmonary fibrosis.
Owens GR; Paradis IL; Gryzan S; Medsger TA; Follansbee WP; Klein HA; Dauber JH
J Lab Clin Med; 1986 Mar; 107(3):253-60. PubMed ID: 3950467
[TBL] [Abstract][Full Text] [Related]
11. [Collageno-vascular diseases and interstitial pulmonary fibrosis. An analysis of diagnostic tests].
Baldi S; Rapellino M; Libertucci D; Obert R; Scappaticci E; Coni F; Revello F; Oliaro A; Botto-Micca F
Minerva Med; 1987 Sep; 78(17):1277-80. PubMed ID: 3670681
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
[TBL] [Abstract][Full Text] [Related]
14. Latent pulmonary inflammation in patients with systemic sclerosis.
Sánchez-Vidaurre S; Simeón CP; Cruz MJ; Fonollosa V; Vilardell M; Morell F; Muñoz X
Arch Bronconeumol; 2012 Jan; 48(1):8-13. PubMed ID: 22133713
[TBL] [Abstract][Full Text] [Related]
15. [Two cases of intrapulmonary lymph node associated with either progressive systemic sclerosis or idiopathic pulmonary fibrosis].
Yoshitomi A; Sato A; Toyoshima M; Suganuma H; Imokawa S; Tamura R; Suda T; Yagi T; Hayakawa H; Chida K
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Sep; 33(9):1003-8. PubMed ID: 8538080
[TBL] [Abstract][Full Text] [Related]
16. The pulmonary manifestations of systemic sclerosis.
Phillips B; Powell RD; Gammon D; Woodring JH
J Ky Med Assoc; 1985 Nov; 83(11):611-6. PubMed ID: 4067388
[No Abstract] [Full Text] [Related]
17. Serial changes in scleroderma and idiopathic interstitial lung disease.
Colp CR; Riker J; Williams MH
Arch Intern Med; 1973 Oct; 132(4):506-15. PubMed ID: 4742404
[No Abstract] [Full Text] [Related]
18. Progression of childhood linear scleroderma to fatal systemic sclerosis.
Mayorquin FJ; McCurley TL; Levernier JE; Myers LK; Becker JA; Graham TP; Pincus T
J Rheumatol; 1994 Oct; 21(10):1955-7. PubMed ID: 7837166
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody.
Steen VD; Lucas M; Fertig N; Medsger TA
J Rheumatol; 2007 Nov; 34(11):2230-5. PubMed ID: 17937469
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.
Várai G; Earle L; Jimenez SA; Steiner RM; Varga J
J Rheumatol; 1998 Jul; 25(7):1325-9. PubMed ID: 9676764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
